Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.84 - $3.24 $552,000 - $972,000
300,000 New
300,000 $666,000
Q4 2023

Feb 14, 2024

SELL
$0.73 - $3.08 $4,015 - $16,940
-5,500 Reduced 2.75%
194,500 $581,000
Q2 2023

Aug 14, 2023

SELL
$1.2 - $1.76 $360,000 - $528,000
-300,000 Reduced 60.0%
200,000 $278,000
Q1 2023

May 15, 2023

BUY
$1.46 - $7.3 $368,650 - $1.84 Million
252,500 Added 102.02%
500,000 $795,000
Q4 2022

Feb 14, 2023

BUY
$5.09 - $8.5 $1.26 Million - $2.1 Million
247,500 New
247,500 $1.54 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $147M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.